组织蛋白酶 K (Cat K) 是一种主要的半胱氨酸蛋白酶和在破骨细胞中表达的高效胶原酶。Cat K 抑制剂是治疗骨质疏松症的抗吸收剂。以先导化合物1x为例的新型组织蛋白酶 K 抑制剂支架被用作设计和合成总共 61 种以前未曾报道过的衍生物的模板。探索性构效关系分析确定了有效的 Cat K 抑制剂A22,其对Cat K的 IC 50值为 0.44 μM 。铅化合物1x. 表面等离子体共振分析证实了A22与 Cat K的体外结合。分子对接研究表明, A22在 Cat K 的活性口袋内有几个有利的相互作用位点。此外, A22还在体外阻断了活性破骨细胞并增加了斑马鱼的脊柱骨密度,其中它显示出高于市售治疗性骨代谢剂依替膦酸二钠的活性。A22代表了一种非常有前途的先导化合物,可用于开发用作 Cat K 的正构抑制剂的新型抗吸收剂。
Synthesis, characterization, biological evaluation, and computational study of benzimidazole hybrid thiosemicarbazide derivatives
作者:Prachi T. Acharya、Zeel A. Bhavsar、Divya J. Jethava、Dhanji P. Rajani、Edwin Pithawala、Hitesh D. Patel
DOI:10.1002/jhet.4548
日期:2022.12
The antimicrobial, anti-tubercular, antimalarial, and antioxidant properties of a series of benzimidazole hybrid thiosemicarbazide derivatives (7a–o) were investigated in vitro. IR, 1H-NMR, 13C-NMR, and ESI-MS spectra were used to describe and elucidate the synthesized compounds. The majority of the compounds studied have excellent antibacterial and antioxidant properties. In addition, an in silico